CareDx announced that it will present the 24‑month follow‑up results of its ACROBAT study at the 2026 Tandem Meetings, the joint ASTCT and CIBMTR conference in Salt Lake City. The oral presentation is scheduled for Friday, February 6, 2026, at 3:15 p.m. Mountain Time, and the announcement was made on February 3, 2026.
The ACROBAT study is a prospective, multi‑center, blinded trial that enrolled patients with acute myeloid leukemia and myelodysplastic syndromes across 11 U.S. transplant centers. Interim data released earlier in the year reported 93 % sensitivity and 88 % specificity for AlloHeme’s ability to detect relapse. Dr. Ran Reshef, the principal investigator, will be a presenter at the conference.
AlloHeme is an AI‑powered next‑generation sequencing assay that monitors peripheral blood for early relapse after allogeneic hematopoietic cell transplantation. By detecting changes in donor‑recipient chimerism earlier than conventional methods, the test offers the potential for earlier clinical intervention and improved patient outcomes.
The presentation is part of CareDx’s strategy to expand beyond its kidney and heart surveillance products—AlloSure and AlloMap—into hematologic transplant monitoring. CareDx aims to secure broader payer coverage and accelerate a commercial launch, adding a new revenue stream to its diversified transplant‑focused portfolio. An investor webcast and conference call on February 12, 2026 will discuss the study findings and outline the launch timeline.
Presenting the 24‑month data at the high‑profile Tandem Meetings provides CareDx with significant credibility and visibility. Successful validation could position the company as a leader in transplant diagnostics and enable it to capture a larger share of the growing market, marking a key milestone in its growth strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.